Latest From Achaogen Inc.
Cormedix prepares NDA submission for Neutrolin for prevention of catheter-related blood stream infections, aiming to become the third approval under the US FDA’s Limited Population Pathway.
Antimicrobial specialist Destiny Pharma aims to enlist a pharma partner later this year to help advance and launch its lead asset for preventing post-surgical infections.
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.
- Large Molecule
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Achaogen Inc.
- Senior Management
Blake Wise, CEO
Zeryn Sarpangal, CFO
Janet Dorling, Chief Commercial Officer
- Contact Info
Phone: (650) 800-3636
1 Tower Pl., Ste. 300
South San Francisco, CA 94080
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.